Hereditary Hemorrhagic Telangiectasia (HHT) Center
HHS-HRSA Forecasted HRSA-26-092Description
The purpose of the Hereditary Hemorrhagic Telangiectasia (HHT) Center Program is to reduce illness and death related to HHT by partnering with clinical center to expand access and coordination of care; creating innovative strategies that support clinicians with identifying and diagnosing HHT cases; and developing a de-identified, aggregate patient data registry to better understand this rare disease and its treatment outcomes.
Eligibility
Community-based organizations that meet one of the entity types listed as eligible. "Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.
Funding Details
- Award Floor
- Not specified
- Award Ceiling
- $2,900,000.00
- Total Estimated Funding
- $2,900,000.00
- Expected Awards
- 1
Key Dates
- Posted
- March 16, 2026
- Closes
- N/A
- Archive Date
- July 23, 2026
Agency Information
- Agency Name
- HHS-HRSA
- Agency Code
- HHS-HRSA
- Funding Instrument
- Other